• CEO of Oscotec
    Kim Jung-kun

    Doctor-turned-entrepreneur leads new drug development, achieves strong results with lung cancer treatment lazertinib

    Last Updated on Feb 12, 2025

    copy_url  Copy Url : https://www.koreawho.com/profile/KimJungkun

Life Summary
Kim Jung-kun is the CEO of Oscotec. He leads Oscotec under a co-CEO system alongside CEO Yoon Tae-young.

While developing new drugs, he focuses on enhancing corporate value and shareholder value.

He was born on February 20, 1960, in Chuncheon, Gangwon Province.

He graduated from the School of Dentistry at Seoul National University. He earned a master's degree in dentistry and a doctorate in biochemistry from the graduate school of Seoul National University.

He worked as a professor in the Department of Biochemistry at Dankook University’s College of Dentistry.

After serving as a researcher at Harvard Medical School in the United States and as the director of the Korea Institute of Biomaterials, he founded Ostek in 1998 and started a bone grafting business.

After transitioning to new drug development, he developed Lazertinib, an EGFR lung cancer treatment candidate.

He possesses strong determination, drive, and perseverance.

#Oscotec #KimJungkun #biotechnology #newdrugdevelopment #Lazertinib #EGFR #lungcancertreatment #biopharmaceuticals #HarvardMedicalSchool #SeoulNationalUniversity